Novartis’s Capmatinib Shows High Response Rates In NSCLC

AACR Lung Cancer Plenary Also Included Spectrum’s Poziotinib

 
• By Mandy Jackson
  
lung illustration
Phase II capmatinib and poziotinib data were presented at AACR
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D